Data protection and life sciences

Copyright © 2025 LexisNexis

Personal data is at the very core of every life science business. Life sciences companies handle significant amounts of personal data and are reliant upon the collection and use of personal data, which often includes sensitive health-related data, in order to carry out key business functions. For example, conducting clinical trials on patients, collecting data on drug safety and adverse reactions in order to comply with pharmacovigilance requirements, and collecting genetic information for the development of personalised medicines all rely on the collection and processing of data relating to individual data subjects. Consequently, it is vitally important that life sciences companies understand, and are in compliance with, the strict rules that apply to the processing of personal data.

This Overview provides an introduction to the application of the data protection regimes to key areas of the life sciences under the EU General Data Protection Regulation, Regulation (EU) 2016/679 (EU GDPR) and the United Kingdom General Data Protection Regulation, Assimilated Regulation (EU) 2016/679 (UK GDPR) (together the ‘GDPR regimes’).

Assimilated law is the name given to retained EU law (‘REUL’) which remains in force after

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest Life Sciences News

New MDCG guidance on the interplay between the MDR/IVDR and the EU AI Act

Life Sciences analysis: Hélène Boland, senior associate and Fabien Roy, partner of Hogan Lovells, consider the key takeaways from the MDCG 2025-6 guidance on the interplay between the MDR/IVDR and the EU AI Act.

DHSC announces AI-powered NHS safety monitoring system for 2025 rollout

The Department of Health and Social Care (DHSC) has announced the development of AI system to monitor National Health Service (NHS) patient safety in real time. The system, which forms part of the government's ‘10 Year Health Plan,’ will analyse NHS databases to identify safety concerns and trigger Care Quality Commission (CQC) inspections. Initial implementation begins November 2025 with the Maternity Outcomes Signal System, designed to flag higher than expected rates of adverse outcomes. The system will operate through the NHS Federated Data Platform, enabling healthcare staff to access information in a single location. CQC inspection teams will investigate concerns raised by the system and implement necessary interventions.

MHRA announces AI Airlock expansion and joins global health AI regulatory network

The Medicines and Healthcare products Regulatory Agency (MHRA) has opened applications for an expanded AI Airlock programme following last year's pilot. The agency has also become the first founding member of Health AI's new global network of health regulators, aimed at sharing early warnings on safety and shaping international standards. Additionally, MHRA's Centre of Excellence for Regulatory Science and Innovation (CERSI) partner RADIANT has launched an Innovator Support Programme, while the agency prepares to publish Good Machine Learning Practice guidance to align with international principles. These initiatives form part of MHRA's strategy to balance innovation with patient safety in AI medical devices.

Team NB releases updated position paper on IVDR software classification

The European Association of Medical devices Notified Bodies (Team NB's) IVD Software Working Task Force, representing 15 notified bodies, has published version 2 of its position paper on software classification under Regulation (IVDR) (EU) 2017/746 (In Vitro Diagnostic Medical Devices Regulation (IVDR)). The updated document features a simplified decision tree and refined terminology for software classification examples. The position paper aims to provide clarification on the classification of software products under IVDR requirements, offering updated guidance for manufacturers and notified bodies.

View Life Sciences by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an
What is the difference between an appeal and a review?

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

Late payment penalties—inheritance tax

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

Contributory negligence in personal injury claims

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an